Exane Derivatives’s Twist Bioscience TWST Stock Holding History

Exane Derivatives’s Portfolio TWST Stock Details TWST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,592	Closed	-$177K	–	954
2022 Q1	$177K	Buy	+3,592	New	+$199K	0.05%	368
2021 Q4	–	Sell	-3,623	Closed	-$388K	–	1004
2021 Q3	$388K	Hold	3,623	–	–	0.09%	237
2021 Q2	$436K	Buy	3,623 +1,944	+116%	+$226K	0.1%	214
2021 Q1	$208K	Buy	+1,679	New	+$255K	0.06%	292

Other funds holding TWST

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Exane Derivatives's TWST Position: Q2 2022 in Review

Exane Derivatives sold out of Twist Bioscience (TWST) in Q2 2022, closing a stake of 3,592 shares — an estimated $177K sold.

Exane Derivatives first reported a position in TWST in Q1 2021 and held it in 4 quarters. The position peaked at $436K in Q2 2021. 203 funds tracked by Wall St. Rank hold TWST as of Q2 2022.

Exane Derivatives reported no remaining Twist Bioscience position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 3,592 Twist Bioscience shares in Q2 2022, an estimated $177K.
Exane Derivatives first reported a position in Twist Bioscience in Q1 2021 and held it in 4 quarters.
Exane Derivatives's Twist Bioscience position peaked at $436K in Q2 2021.
203 funds tracked by Wall St. Rank held Twist Bioscience as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.